IP Library Granted Patent US 7,172,629
Granted Patent B2
US 7,172,629 · App. 09/923,117 · Granted Feb 6, 2007

Osteogenic paste compositions and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,172,629
App. No.
09/923,117
Granted
Feb 6, 2007
Kind
B2
Abstract

Described are osteogenic paste compositions with enhanced osteoinductive properties for use in bone repair. Compositions comprising a quickly resorbable paste carrier, a more slowly resorbed mineral matrix, and Bone Morphogenetic Protein (BMP) or other osteogenic factor are described which enable increased osteoinductive activity while retaining a reliable scaffold for the formation of new bone at the implant site. Methods for making and methods for therapeutic use of the compositions are also disclosed.

Claims (80)

1. An osteogenic paste composition effective for the induction of new bone growth in a human patient, comprising:

a resorbable paste carrier comprising a macromolecular carrier material;

an osteogenic factor comprising a bone morphogenic protein, wherein said bone morphogenic protein is effective to stimulate both osteoblasts and osteoclasts when administered to a human, and wherein said bone morphogenic protein is incorporated into said paste composition in such an amount as to stimulate the osteoclasts sufficiently to cause an increase in the rate of resorption of the macromolecular carrier material when the paste composition is implanted in the human; and

a porous particulate mineral in an amount of at least 20% by volume of the composition, said amount being effective to provide a scaffold for bone ingrowth as the resorbable paste carrier is resorbed.

2. The composition of claim 1 which further comprises demineralized bone matrix.

3. The composition of claim 2 wherein the ratio of demineralized bone matrix to resorbable carrier is between about 1:4 and about 3:2 by weight.

4. The composition of claim 2 wherein the composition comprises 5–45% by weight resorbable carrier.

5. The composition of claim 1 wherein the resorbable carrier is flowable at temperatures above the body temperature of the mammal, but transitions to a non-flowable mass at or slightly above said body temperature.

6. The composition of claim 1 wherein the mineral is selected from the group consisting of bone particles, bioglass, tricalcium phosphate, hydroxyapatite, corraline, hydroxyapatite, biocompatible ceramic and non-resorbable biocompatible organic polymer.

7. The composition of claim 1 wherein the mineral comprises tricalcium phosphate, biphasic calcium phosphate, or hydroxyapatite particles having an average particle diameter of about 0.050 to about 5.0 mm.

8. The composition of claim 1 wherein the mineral comprises mammalian bone particles having a particle size of about 0.050 to about 5.0 mm.

9. The composition of claim 1 wherein the mineral comprises cortical human bone particles having an average particle diameter of about 0.050 to about 5.0 mm.

10. The composition of claim 1 further comprising one or more osteogenic enhancing factors selected from the group consisting of osteogenic progenitor cells, autographic bone marrow, allographic bone marrow, transforming growth factor-beta, fibroblast growth factor, platelet derived growth factor, insulin-like growth factor, microglobulin-beta, antibiotics, antifungal agents, wetting agents, glycerol, steroids and non-steroidal anti-inflammatory compounds.

11. The composition of claim 1 wherein the mineral constitutes about 20% to about 80% by volume of the composition.

12. A method for inducing bone growth in a primate, comprising implanting in the primate a composition according to claim 1 , at a site at which bone growth is desired.

13. The method of claim 12 , wherein the site is in the spine of the primate.

14. The method of claim 13 , which is a spinal fusion.

15. The method of claim 14 , wherein the spinal fusion is an interbody spinal fusion.

16. The method of claim 14 , which is a posterolateral spinal fusion.

17. The method of claim 14 , wherein the fusion includes a fusion between transverse processes of adjacent vertebrae.

18. The method of claim 13 , wherein the primate is a human.

19. A method of performing a spinal fusion in a human, comprising implanting between adjacent vertebrae to be fused an effective amount of a composition according to claim 1 .

20. The method of claim 19 , wherein the composition is implanted in combination with a load bearing device.

21. The composition of claim 1 , wherein:

said macromolecular carrier molecule comprises collagen.

22. The composition of claim 1 , wherein:

said resorbable paste carrier comprises a macromolecular carrier component consisting essentially of collagen.

23. The composition of claim 1 , wherein:

said macromolecular carrier molecule comprises gelatin.

24. The composition of claim 1 , wherein:

said bone morphogenic protein comprises BMP-2.

25. The composition of claim 24 , wherein:

said BMP-2 comprises recombinant human BMP-2.

26. The composition of claim 1 , wherein:

said bone morphogenic protein comprises BMP-4 or BMP-b 7 .

27. The composition of claim 1 , wherein:

said bone morphogenic protein comprises BMP-2; and

said porous particulate mineral comprises particulate bicalcium phosphate.

28. The composition of claim 27 , wherein:

said bicalcium phosphate has a tricalcium phosphate:hydroxyapatite weight ratio in the range of about 80:20 to about 90:10.

29. The composition of claim 27 , wherein said BMP-2 is recombinant human BMP-2, and wherein the recombinant human BMP-2 is incorporated into the paste composition at a weight ratio of about 1:100 to about 1:500 relative to the overall paste composition.

30. A method of performing a spinal fusion in a human, comprising implanting between adjacent vertebrae to be fused an effective amount of a composition according to claim 27 .

31. An osteogenic implant material effective for the induction of new bone growth in a mammal, comprising:

a resorbable paste carrier comprising gelatin, the resorbable carrier formulated to be flowable at temperatures above the body temperature of the mammal, and to transition to a non-flowable mass at said body temperature;

demineralized bone matrix;

an osteogenic factor comprising a bone morphogenic protein, wherein said bone morphogenic protein is effective to stimulate both osteoblasts and osteoclasts when administered to a human, and wherein said bone morphogenic protein is incorporated into said paste composition in such an amount as to stimulate the osteoclasts sufficiently to cause an increase in the rate of resorption of the macromolecular carrier material when the paste composition is implanted in the human; and

a particulate mineral having an average particle size of about 0.050 to about 5.0 mm, said mineral constituting at least 20% by volume of said composition.

32. The composition of claim 31 wherein the mineral constitutes about 20% to about 80% by volume of the composition.

33. The composition of claim 31 wherein the mineral comprises human bone particles.

34. The composition of claim 31 wherein the mineral comprises non-human bone particles, said particles having been treated to reduce their immunogenicity in humans.

35. The composition of claim 31 , wherein:

said carrier comprises gelatin.

36. The composition of claim 31 , wherein:

said bone morphogenic protein comprises BMP-2.

37. The composition of claim 36 , wherein:

said BMP-2 comprises recombinant human BMP-2.

38. The composition of claim 31 , wherein:

said bone morphogenic protein comprises BMP-4 or BMP-7.

39. The composition of claim 31 , wherein:

said bone morphogenic protein comprises BMP-2; and

said porous particulate mineral comprises particulate bicalcium phosphate.

40. The composition of claim 39 , wherein:

said bicalcium phosphate has a tricalcium phosphate:hydroxyapatite weight ratio in the range of about 80:20 to about 90:10.

41. A method for inducing bone growth in a primate, comprising:

heating an effective amount of an osteogenic paste composition to a temperature at which it is flowable, said osteogenic implant material comprising a resorbable paste carrier that is flowable at temperatures above the body temperature of the primate, but which transitions to a non-flowable mass at or slightly above said body temperature; an osteogenic factor that stimulates osteoblasts and osteoclasts when administered to a primate, and wherein said osteogenic factor is incorporated in said paste composition in such an amount as to stimulate the osteoclasts sufficiently to cause an increase in the rate of resorption of the resorbable paste carrier when the paste composition is implanted in the primate; and; and, a particulate mineral effective to provide a scaffold for bone ingrowth as the resorbable carrier is resorbed, said mineral constituting at least 20% by volume of the paste composition;

implanting said osteogenic paste composition at a site of desired new bone formation; and

cooling the osteogenic paste composition to a temperature sufficient to transition the osteogenic paste composition to a non-flowable mass.

42. The method of claim 41 wherein the implant material further comprises demineralized bone matrix.

43. The method of claim 41 wherein the primate is a human.

44. A method of performing a spinal fusion in a human subject,

comprising:

providing an osteogenic composition including a resorbable paste carrier including a macromolecular carrier material, a bone morphogenic protein, and a particulate mineral material, wherein said bone morphogenic protein is effective to stimulate both osteoblasts and osteoclasts when administered to the human subject, wherein said bone morphogenic protein is incorporated into said paste composition in such an amount as to stimulate the osteoclasts sufficiently to cause an increase in the rate of resorption of the macromolecular carrier material when the paste composition is implanted in the human subject, and wherein said particulate mineral constitutes at least 20% by volume of the paste composition and is effective to provide a scaffold for bone ingrowth as the resorbable carrier is resorbed, said scaffold effective to remain in the human subject for a period of time sufficient for formation of osteoid in a volume in which bone growth is desired; and

implanting said osteogenic paste composition in the human patient in an interbody space between adjacent vertebrae or between transverse processes of adjacent vertebrae, wherein said osteogenic paste composition induces bone formation in a volume between the adjacent vertebrae and said particulate mineral provides a scaffold for bone ingrowth that remains until osteoid has formed in the volume between the adjacent vertebrae that will receive bone ingrowth for fusion of the adjacent vertebrae.

45. The method of claim 44 , wherein:

said resorbable macromolecular carrier material comprises collagen.

46. The method of claim 45 , wherein:

said bone morphogenic protein comprises human BMP-2.

47. The method of claim 46 , wherein:

said particulate mineral material comprises biphasic calcium phosphate.

48. The method of claim 44 , wherein said resorbable macromolecular material comprises gelatin, hyaluronic acid, carboxymethyl cellulose, or collagen.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT T0 REMOVE APPLICATION NUMBER PREVIOUSLY RECORDED AT REEL: 018573 FRAME: 0086. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Oct 7, 2014
From: SDGI HOLDINGS, INC.
To: WARSAW ORTHOPEDIC, INC
Reel/Frame 033904/0891 →
MERGER Recorded Dec 1, 2006
From: SDGI HOLDINGS, INC.
To: WARSAW ORTHOPEDIC, INC.
Reel/Frame 018573/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2003
From: MCKAY, WILLIAM F.
To: SDGI HOLDINGS, INC.
Reel/Frame 014620/0080 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2003
From: MCKAY, WILLIAM F.
To: SDGI HOLDINGS, INC.
Reel/Frame 014170/0556 →